Fecal Transplants Show Mixed Results for Boosting Cancer Immunotherapy

Fecal microbiota transplantation (FMT) has emerged as a potential game-changer for cancer immunotherapy, but new research reveals a complex picture of both promise and peril. This comprehensive review synthesizes evidence from multiple clinical trials examining how FMT affects immune checkpoint inhibitor (ICI) treatments like anti-PD-1 and anti-CTLA-4 therapies.

The gut microbiome plays a crucial role in immune system function, influencing T cell differentiation, inflammatory responses, and antitumor immunity. ICIs work by removing the brakes on immune cells, allowing them to attack cancer more effectively. However, only some patients respond to these treatments, and emerging evidence suggests gut bacteria composition may determine success or failure.

Clinical results with FMT-ICI combinations show dramatic variability. In one melanoma trial, 40% of ICI-resistant patients regained responsiveness after FMT, with some achieving complete remission. However, other studies found no significant benefit, and some suggested potential harm. The SER-401 trial, testing a specific bacterial formulation in melanoma patients, failed to show advantages over standard ICI therapy alone.

The review identifies several factors driving these inconsistent outcomes. Donor selection criteria vary widely between studies, with some using healthy volunteers while others select donors based on specific bacterial profiles. Recipient characteristics—including prior antibiotic use, baseline microbiome composition, and cancer type—also influence results. Administration methods range from colonoscopy to oral capsules, potentially affecting transplant success.

Researchers emphasize that FMT's effects on cancer immunity are bidirectional. While beneficial bacteria can enhance T cell function and promote anti-tumor responses, FMT may also introduce immunosuppressive microbes that could worsen outcomes. The timing of FMT relative to ICI treatment, preparation methods, and post-transplant monitoring all require standardization. The authors call for large-scale randomized trials, standardized protocols, and integration of artificial intelligence to optimize donor-recipient matching and predict treatment responses.